Last reviewed · How we verify
Isovue and Visipaque in Renally Impaired Patients Undergoing CT
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Details
| Lead sponsor | Bracco Diagnostics, Inc |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 150 |
| Start date | 2004-11 |
| Completion | 2006-02 |
Conditions
- Contrast Induced Nephropathy
Interventions
- Iopamidol 370 mgI/mL
Primary outcomes
- Increase in SCr at 48-72 hours post dose
Countries
United States